Stockholm’s BioLamina secures €20 million EIB loan to scale cell therapies for chronic diseases
· eu startups
AI Briefing
- BioLamina secures €20 million EIB loan to scale cell therapies for chronic diseases
- The loan is structured as venture debt to support the company's expansion
- The EIB financing will enable BioLamina to accelerate its development of innovative cell therapies
Advertisement